Kornimate/medical-research-clean huggingface dataset:
comparison of efficacy of double dose oral terbinafine vs itraconazole in treatment of dermatophyte infections of skin.

Conditions: Dermatophyte Infection; Terbinafine Adverse Reaction; Itraconazole Adverse Reaction

Summary: study would be conducted to compare the efficacy and safety of double than usual dose oral terbinafine versus itraconazole in treatment of dermatophyte infections of skin in patient presenting at dermatology department of pak emirates military hospital, rawalpindi, pakistan.

* study would be a randomized controlled trial, in which 120 subjects would be randomly divided into two equal groups of 60 each. * each group would be prescribed double than usual dose of terbinafine(250 mg twice daily) or itraconazole(100mg twice daily) for 2 weeks initially. treatment may be extended to 4 weeks if cure has not been achieved. patients will be diagnosed and followed on the basis of classical clinical features of dermatophyte infections and microscopic potassium hydro-oxide slide preparation for fungal hyphae and spores. liver function tests will be checked on day 0, 14 and 28. individuals aged 15-50 years with one or no co-morbidity will be included in the study. study will be conducted over a period of 6-8 months.

Eligibility criteria:
inclusion criteria: * individuals with dermatophyte skin infection, aged 15-50 years with one or no co-morbidities. exclusion criteria: * individuals with two or more co-morbidities or known cases of chronic liver disease.

Keywords: double dose oral terbinafine oral itraconazole dermatophyte skin infection randomized controlled trial
diabetes mellitus and hiv study in mwanza

Conditions: Diabetes Mellitus; HIV/AIDS

Summary: emerging evidence from high-income countries suggests that diabetes mellitus is become a major health problem among hiv-infected patients. however, due to differences in social, environmental, and genetic factors data from high-income countries can not be extrapolated directly to low-income countries. this study investigates hiv, art, inflammation, and body composition changes as risk factors for diabetes mellitus among hiv-infected patients in tanzania.

access to antiretroviral therapy (art) is increasing rapidly in low-income countries and hiv-infected patients initiate art much earlier. as a result, these patients have prolonged life spans and, hence, longer hiv and art exposure. emerging data from developed countries suggest that hiv-infected patients have a higher risk than hiv-uninfected people of developing diabetes mellitus (dm) and other non-communicable diseases. the excess diabetes risk is probably related to multiple factors including hiv-associated inflammation, the use of some antiretroviral therapy (art) regimens, and body composition changes associated with hiv and art. as a result, hiv-infected populations may develop dm at a younger age and may have a higher mortality if management is not optimal as may be the case in resource-limited countries of sub-saharan africa (ssa). most of the data to-date on hiv and dm are from high-income countries, and data in ssa are few and inconsistent. because of differences in genetic composition as well as environmental factors including high burden of infectious diseases in resource-limited settings, data from high-income countries cannot be extrapolated and reliably used to improve quality of dm care among hiv patients in ssa. the objective of this study is to investigate if hiv, art, and body composition changes occurring during art use are associated with higher risk of dm as well as other risk factors for cardiovascular diseases in tanzanian patients, and examine if hiv increases the risk of dm associated complications. this study is funded by the danish ministry of foreign affairs from 2016 to 2021.

Eligibility criteria:
inclusion criteria: * for existing cohorts, patients should come from nut-tb or nustart cohorts * for new hiv cohort, patients should be hiv positive art naive, hiv negative participants will be come from the same neighborhood as newly recruited hiv positive patients * age will be 18 years and above * mwanza region residency * not planning to relocate outside mwanza within the study period exclusion criteria: * very severe illness

Keywords: pre-diabetes diabetes mellitus hiv art body composition inflammation insulin resistance beta-cell function pre-hypertension hypertension
glutaminergic agents for cocaine abuse - 5

Conditions: Cocaine-Related Disorders

Summary: the purpose of this study is to evaluate glutaminergic agents for cocaine abuse.


Eligibility criteria:
please contact site for information.

Keywords: cocaine
efficacy and safety of seroquel plus mood stabilizer in the maintenance of bipolar i disorder

Conditions: Bipolar Disorder

Summary: the purpose of this study is to determine whether quetiapine when used as adjunct to lithium or divalproex is safe and effective in the maintenance treatment of adult patients with bipolar i disorder. the study consists of enrollment and 2 phases, the open-label treatment phase and the randomized treatment phase. please note: seroquel sr and seroquel xr refer to the same formulation. the sr designation was changed to xr after consultation with fda.


Eligibility criteria:
inclusion criteria: open-label * a diagnosis of bipolar i disorder, most recent episode manic (296.4x), or bipolar i disorder, most recent episode depressed (296.5x), or bipolar i disorder, most recent episode mixed (296.6x), with or without psychotic features, as defined by diagnostic and statistical manual of mental disorders - fourth edition (dsm-iv) * at least 1 manic, depressed, or mixed episode in the 2 years prior to the index episode. * able to understand and comply with the requirements of the study. exclusion criteria: open-label * diagnosis of an anxiety disorder as defined by dsm-iv, which was treated with medication within the past year. * known intolerance or lack of response to quetiapine fumarate or to the assigned mood stabilizer, as judged by the investigator. * previously randomized into this study or d1447c00126

Keywords: bipolar i disorder manic depressive disorder manic depression, mixed
tumor hypoxia of head-and-neck cancer underwent radiation therapy measured with f-18-fmiso

Conditions: Head and Neck Neoplasms

Summary: the purpose of this study is to describe the regional and global tumor hypoxia in head-and-neck cancer during percutaneous radiation therapy


Eligibility criteria:
inclusion criteria: * histologically confirmed head-and-neck cancer not curable by surgery * karnofsky \> 70% * tumor volume and localisation allow curative radiotherapy * written consent exclusion criteria: * metastases * earlier radiation therapy of head and neck * pregnancy * secondary malignancy excluding dermal carcinoma and tis-carcinoma of cervix uteri * psychiatric impairment

Keywords: head-and-neck cancer radiation therapy f-18-fmiso
chlorthalidone in chronic kidney disease

Conditions: Renal Insufficiency, Chronic; Hypertension

Summary: it is estimated that in the united states there are approximately 8 million individuals who have moderate to severe chronic kidney disease (ckd). among them hypertension is common and is often poorly controlled due to an expanded volume state; diuretics are frequently prescribed. loop diuretics are potent and effective in lowering blood pressure (bp) but their use is associated with acute kidney injury. thiazide diuretics, on the other hand, are less potent, their use may be associated with less acute kidney injury, but as yet there are no firm data to support that thiazide diuretic therapy can improve bp among subjects with advanced ckd. the investigators found 13 studies on the use of thiazide diuretics in advanced ckd either alone or in combination with loop diuretics and concluded that thiazides may be useful. thiazides cause a negative na balance, increase na excretion by 10-15% and weight loss by 1-2 kg in observational studies. observational data show that thiazides lead to an improvement in seated clinic bp of about 10-15 mmhg systolic and 5-10 mmhg diastolic whereas randomized trials show about a 15 mmhg reduction in mean bp. randomized trials had only between 7 and 23 subjects each; accordingly, larger studies are needed to evaluate their safety and efficacy in moderate to advanced ckd.

this is a placebo-controlled, double-blind, randomized controlled trial of chlorthalidone (ctd) in patients with ckd and poorly controlled hypertension

Eligibility criteria:
inclusion criteria: 1. age greater than 18 years. 2. calculated glomerular filtration rate (gfr) by 4-component modification of diet in renal disease (mdrd) formula \< 30 ml/min/1.73m2 but ≥15 ml/min/1.73m2. the hospital laboratory uses isotope dilution mass spectrometry (idms) calibrated creatinine and the appropriate formula is used to estimate gfr. 3. hypertension. this is defined as bp of either ≥130 systolic or ≥80 mmhg by 24-hour ambulatory bp monitoring. 4. treatment with antihypertensive drugs: this would require the use of at least one antihypertensive drug. one of the drugs should be either an angiotensin converting enzyme (ace) inhibitor or angiotensin receptor blocker (arb). if these are contraindicated then use of a beta-blocker is required prior to randomization. exclusion criteria: 1. use of thiazide or thiazide-like drugs in the previous 12 weeks. 2. use of furosemide in a dose \>200 mg/d. 3. bp of either ≥160 systolic or ≥100 mmhg by 24-hour ambulatory bp monitoring. 4. expected to receive renal replacement therapy within the next 3 months. 5. myocardial infarction, heart failure hospitalization, or stroke ≤3 months prior to randomization. 6. pregnant or breastfeeding women or women who are planning to become pregnant or those not using a reliable form of contraception (oral contraceptives. condoms and diaphragms will be considered reliable). 7. known hypersensitivity to thiazide or sulfa drugs. 8. organ transplant recipient or therapy with immunosuppressive agents.
ragweed-spire follow-on study

Conditions: Rhinoconjunctivitis; Ragweed Allergy

Summary: the purpose of this study is to determine the efficacy of ragweed-spire 12 months after the initial dose.


Eligibility criteria:
inclusion criteria: ° previously randomised into and completed at least 6 of 8 treatment visits in study tr006 exclusion criteria: * subject or investigator have been informed of treatment received in study tr006 * subjects with significant allergy to animal dander * any allergen immunotherapy since completing study tr006 or use of prohibited therapies * history of recurrent acute sinusitis or chronic sinusitis * received treatment with an investigational drug within 4 weeks of screening * unable to understand study requirements or unable to communicate clearly with investigator

Keywords: ragweed allergy rhinoconjunctivitis immunotherapy ragweed-spire
genetic analysis of childhood obesity

Conditions: Obesity

Summary: identify news genetic causes of different type of obesity (syndromic, familial or isolated obesity) by highlighting new mutations or new implied genes


Eligibility criteria:
inclusion criteria: * bmi \> curve of iotf 30 (international obesity task force) * age: between 6 months old and 18 years old * child presenting syndromic, isolated or familial obesity. exclusion criteria: * common obesity * impossibility for blood sampling * impossibility to receive information * participation refusal of one of the parents * refusal to sign the informed consent * neither healthcare coverage nor insurance

Keywords: childhood obesity genetics
myvhl: patient natural history study

Conditions: Von Hippel-Lindau Disease; Hereditary Leiomyomatosis and Renal Cell Cancer; Birt-Hogg-Dube Syndrome; SDHB Gene Mutation

Summary: myvhl is a multi-patient database which helps researchers identify patterns across vhl patients. myvhl provides you -and researchers -with more complete information about vhl, like how your lifestyle, medications, and other factors impact the disease and quality of life. these insights help you better understand the condition and help researchers know where to focus their efforts. due to its rarity, there is less understanding of vhl and the factors that may have an impact. the data individuals provide in myvhl helps researchers identify and uncover factors that may increase risk, inhibit or slow tumor growth, or lead to an effective cure.


Eligibility criteria:
inclusion criteria: * all patients with von hippel-lindau disease (vhl) exclusion criteria: -

Keywords: vhl bhd hlrcc sdhb myvhl
phantom limb pain: efficacy of non-invasive sensory feedback through the prosthesis

Conditions: Phantom Limb Pain

Summary: amputation of a limb may result from trauma or surgical intervention. the amputation traumatically alters the body image, but often leaves sensations that refer to the missing body part. in 50-80% amputees, neuropathic pain develops, also called phantom limb pain (plp). both peripheral and central nervous system factors have been implicated as determinants of plp. also, plp may be triggered by physical (changes in the weather) and psychological factors (emotional stress). recent evidence suggests that plp may be intricately related to neuroplastic changes in the cortex, and that these changes may modulated by providing sensory input to the stump or amputation zone. a non-invasive clinical trial will test the effectiveness of non-invasive pressure sensory feedback build into a hand prosthesis to alleviate phantom limb pain.

during the pre-screen phase the investigators will assess whether the patient experiences referred phantom limb sensations or pain. in the case that the patient does experience referred sensations on the stump the investigators will map the areas where the sensation occurs on the stump and utilize this for placement of the surface actuators. in the opposite case, actuators will instead be placed in a matrix structure at the residual limb. as a first step towards applying mechanical stimulation, the sensation thresholds (the level of stimulation where the subject first reports a sensation) have to be determined. the outcome of this procedure is a minimum of stimulation amplitude that can be applied for each stimulation site. a first choice would be to use the referred map to place actuators. however, amputees have different phantom maps and also the number of areas varies. a therapy will be defined based on the use of sensory feedback system integrated with the amputees hand prosthesis. the subject should use the hand prosthesis, with sensory feedback, for a duration of minimum 2 h per day during a 4 week period. preferably, the system should be used actively in normal daily activities.

Eligibility criteria:
inclusion criteria: * transradial amputation * amputation should be in a stable phase * other treatments for plp tried with poor result * plp experienced as over 6 on a visual analogue scale exclusion criteria: * cognitive impairment * pregnancy * history of active substance abuse disorder * acquired brain injury with residual impairment * intelligence disability * neurologic or musculoskeletal disease or other diseases that may affect the function of nervous system * pacemaker * dermatologic condition
outcomes comparison between bone resection and subperiosteal dissection for specific type of soft tissue sarcoma

Conditions: Soft Tissue Sarcoma; Cortical Contact

Summary: the purpose of this study is to assess whether bone resection for thigh soft tissue sarcoma with cortical involvement of the adjacent bone result in better local control and survival compared to sub-periosteal dissection. investigators also aim to find out the prognostic factors for clinical outcomes in this group of patients.


Eligibility criteria:
inclusion criteria: 1. patients developed thigh soft tissue sarcoma, defined as lesion located below the plane of the lesser trochanter and above the plane of the femoral condyle. 2. received primary limb-salvage surgery at our center. 3. soft tissue sarcoma with only cortical contact of the adjacent bone based on preoperative imaging 4. minimum of 2-year follow up exclusion criteria: 1. diagnosis was well differentiated liposarcoma 2. patients with metastatic disease at the time of presentation 3. soft tissue sarcoma displayed frank osseous invasion (eg. medullary canal invasion)
intraarticular collagen in patients with gonarthrosis

Conditions: Gonarthrosis

Summary: the objective of this clinical trial is to verify the effectiveness of polyvinyl pyrrolidone collagen in all patients with symptomatic gonarthrosis grades ii-iv in patients over 40 years of age. the main objectives that this study aims to answer are the following: 1. - document the effectiveness of intra-articular polyvinylpyrrolidone collagen in the treatment of symptomatic gonarthrosis. 2. - compare the intensity of pain, the degree of stiffness and functionality of the joint, prior to application and one month after the therapeutic intervention. 3. - identify demographic, clinical and therapeutic factors that influence the effectiveness of intra-articular pvp collagen in the treatment of symptomatic gonarthrosis. patients diagnosed with symptomatic gonarthrosis grade ii-iv, referred to the physical medicine and rehabilitation service within 3 months, will be selected. two study groups will be assigned: group those who received intra-articular infiltration of pvp collagen, group b: patients who received conservative treatment. through rehabilitation with a home program for one month, in both cases, ena and the womac scale will be evaluated at the beginning of the study and after 4 weeks.

introduction: osteoarthritis is a disorder characterized by progressive deterioration of cartilage in synovial joints, affecting more than 55% of the elderly population, causing significant physical disability, implying a great challenge in medical treatment. material and methods: a sequential, simple randomized clinical trial was carried out in patients diagnosed with symptomatic gonarthrosis grade ii-iv, referred to the physical medicine and rehabilitation service in 3 months, through two study groups: group those who received intra-articular infiltration of collagen pvp, group b: patients who received conservative treatment through rehabilitation with a home program for one month. in both cases, ena and the womac scale were evaluated at the beginning of the study and at 4 weeks.

Eligibility criteria:
inclusion criteria: 1. age over 40 years. 2. both sexes. 3. joint stiffness less than 30 minutes. 4. crepitus in the knee joint. 5. pain in one or both knees lasting more than three months. 6. continuous pain quantified in \>5 analog numerical scale. 7. patients entitled to the mexican social security institute. 8. radiological criteria for gonarthrosis in phases ii, iii, iv. 9. patients not candidates for surgical treatment. exclusion criteria: 1. rheumatoid arthritis, gout or chondrocalcinosis. 2. treatment with glucosamine, chondroitin, diacerein, silver non-saponifiables or slow-acting drug in the last three months. 4. anticoagulant treatment. 5. paget's disease. 6. treatment with viscosupplementation in the last six months. 7. patients not entitled to the mexican social security institute.

Keywords: gonarthrosis collagen infiltration
zurig (febuxostat) 40mg efficacy and safety trial

Conditions: Hyperuricemia

Summary: febuxostat is a potent, nonpurine, selective inhibitor of xanthine oxidase that exhibits antihyperuricemic activity by reducing the formation of uric acid. the investigators conducted an interventional, two-arm, randomized, open label pilot study on patients with serum urate level ≥ 6.8 mg/dl. patients were treated with febuxostat 40 mg tablets or allopurinol 300 mg tablets once daily dose for 90 days to determine the efficacy and safety of febuxostat in comparison with allopurinol in hyperuricemic subjects with or without gout.

patients with hyperuricemia (with or without gout) were randomized into two groups. one was treated with febuxostat 40 mg tablets and other with allopurinol 300 mg tablets once daily for 3 months period. gender, age, height, weight, creatinine and alt levels, co-morbidities and other complications were monitored at screening and as per eligibility criteria 50 patients were enrolled in the study. efficacy was determined by monitoring serum uric acid levels during and at the end of treatment. the safety profile has also been monitored during the treatment period. investigator collected and recorded all the data of visits in crf which was analyzed through spss version 20.

Eligibility criteria:
inclusion criteria: 1. both genders from 18 to 75 years of age 2. must have a serum urate level ≥ 6.8 milligram per deciliter (mg/dl) and/or subjects recruited with gout; must meet american college of rheumatology criteria for gout. 3. females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from screening throughout the duration of the study. 4. patient willingly provides written informed consent exclusion criteria: 1. history of significant concomitant illness 2. active liver disease (sgpt\> 1.5 times the upper limit of normal range) 3. severe renal impairment (serum creatinine level \>2mg/dl) 4. any other significant medical condition that would interfere with the treatment, safety or compliance with the protocol, as defined by the investigator 5. cardiac disease or stroke (current or previous history) 6. has a known history of infection with hepatitis b, hepatitis c, or hiv 7. has a history of cancer within 5 years prior to the first dose of study medication 8. has a known hypersensitivity to febuxostat or allopurinol or any components of their formulation

Keywords: febuxostat efficacy safety allopurinol hyperuricemia zurig getz pharma